Dyadic and Sorrento Announce Binding Term Sheet to Liecense Dyadic’s Lead
COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Gre





